Amiodarone lung toxicity – ‘amiodarone lung’

Czech version

Authors: Genzor S.; Žurková M.; Sova M.; Kolek V.
Authors‘ workplace: Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc
Published in: Kardiol Rev Int Med 2019, 21(3): 142-144

Overview

The lung is very sensitive to the possible toxic effects of various agents – either caused by direct toxicity or immunity-driven. The number of drugs with proven lung toxicity is increasing, therefore prescribing physicians should know the possible side effects affecting the lungs. The article briefly summarises current knowledge about amiodarone lung toxicity. A case report of a typical example is provided in the second part of the article.

Keywords:

amiodarone – drug-induced lung toxicity

Sources

1. Vašáková M, Polák J, Matěj R. Intersticiální plicní procesy: od etiopatogeneze přes radiologický obraz k histopatologické diagnóze. 2. vyd. Praha: Maxdorf Jessenius 2016.

2. Lošťáková V, Kuna M, Kolek V et al. Polékové postižení plic. Klin Farmakol Farm 2018: 32(4): 21–31.

3. Kolek V. Doporučené postupy v pneumologii. 2. vyd. Praha: Maxdorf Jessenius 2016.

4. Rotmensch HH, Liron M, Tupilski M et al. Possible association of pneumonitis with amiodarone therapy (letter). Am Heart J 1980; 100(3): 412–413. doi: 10.1016/ 0002-8703(80)90165-9.

5. Dusman RE, Stanton MS, Miles WN et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82(1): 51–59. doi: 10.1161/ 01.cir.82.1.51.

6. Camus P, Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Clin Chest Med 2004; 25(1): 65–75. doi: 10.1016/ S0272-5231(03)00144-8.

7. Marchlinski FE, Gansler TS, Waxman HL et al. Amiodarone pulmonary toxicity. Ann Int Med 1982; 97(6): 839–845. doi: 10.7326/ 0003-4819-97-6-839.

8. Gleadhill IC, Wise RA, Shonfeld SA et al. Serial lung function in patients treated with amiodarone: a prospective study. Am J Med 1989; 86(1): 4–10. doi: 10.1016/ 0002-9343(89)90221-0.

9. Kojima S, Kojima S, Ueno H et al. Increased density of the liver and amiodarone-associated phospholipidosis. Cardiol Res Pract 2009; 2009: 598940. doi: 10.4061/ 2009/ 598940.

10. Chuang CL, Chern MS, Chang SC. Amiodarone toxicity in a patient with simultaneous involvement of cornea, thyroid gland, and lung. Am J Med Sci 2000; 320(1): 64–68. doi: 10.1097/ 00000441-200007000-00010.

11. Jessurum GA, Crijns HJ. Amiodarone pulmonary toxicity. BMJ 1997; 314: 619–620.

12. Myers JL, Kennedy JI, Plumb VJ. Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol 1987; 18(4): 349–354. doi: 10.1016/ s0046-8177(87)80164-8.

13. Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity: Recognition and pathogenisis (Part 1). Chest 1988; 93(5): 1067–1075. doi: 10.1378/ chest.93.5.1067.

14. Okayasu K, Takeda Y, Kojima J et al. Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity and consideration of the probable risk of relapse. Intern Med 2006; 45(22): 1303–1307. doi: 10.2169/ internalmedicine.45.1800.

15. Greenspon AJ, Kidwell GA, Hurley W et al. Amiodarone-related post-operative adult respiratory distress syndrome. Circulation 1991; 84 (Suppl 5): 407–415.